Intraperitoneal aerosolized drug delivery: Technology, recent developments, and future outlook

Mohammad Rahimi-Gorji, Leen Van de Sande, Charlotte Debbaut, Ghader Ghorbaniasl, Helena Braet, Sarah Cosyns, Katrien Remaut, Wouter Willaert, Wim Ceelen

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Current therapies for patients with peritoneal metastases (PM) are only moderately effective. Recently, a novel locoregional treatment method for PM was introduced, consisting of a combination of laparoscopy with intraperitoneal (IP) delivery of anticancer agents as an aerosol. This ‘pressurized intraperitoneal aerosol chemotherapy’ (PIPAC)may enhance tissue drug penetration by the elevated IP pressure during CO2 capnoperitoneum. Also, repeated PIPAC cycles allow to accurately stage peritoneal disease and verify histological response to treatment.
This review provides an overview of the rationale, indications, and currently used technology for therapeutic IP nebulization, and discusses the basic mechanisms governing aerosol particle transport and peritoneal deposition. We discuss early clinical results in patients with advanced, irresectable PM and highlight the potential of electrostatic aerosol precipitation. Finally, we discuss promising novel approaches, including nebulization of nanoparticles and prolonged release formulations.
Original languageEnglish
Pages (from-to)105-114
Number of pages10
JournalAdvanced Drug Delivery Reviews
Volume160
Publication statusPublished - 2020

Fingerprint Dive into the research topics of 'Intraperitoneal aerosolized drug delivery: Technology, recent developments, and future outlook'. Together they form a unique fingerprint.

Cite this